• Profile
Close

Lower impact of vonoprazan–amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication

Journal of Gastroenterology and Hepatology Jun 24, 2021

Horii T, Suzuki S, Takano C, et al. - As disruption in the gut microbiome may occur because of Helicobacter pylori eradication, researchers herein examined the short-term impact of minimum antibiotic treatment—a 7-day vonoprazan and low-dose amoxicillin regimen (VA-dual therapy)—on gut microbiota as well as compared it with that of vonoprazan-based triple therapy (VAC-triple therapy). They recruited and randomized 59 patients with H. pylori infection to the VAC-triple therapy or VA-dual therapy groups, according to the first-line H. pylori treatment received. Before treatment initiation as well as 1 and 8 weeks after eradication therapy completion, the patients provided fecal samples for evaluation. Findings suggest that VA-dual therapy induced minimal changes in the diversity and relative abundance of gut microbiota compared with VAC-triple therapy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay